Antitumor activity of bortezomib (PS-341; Velcade) in a phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Chen, CI
White, D
Kouroukis, CT
Stewart, AK
Howson-Jan, K
Larratt, L
Powers, J
Eisenhauer, E
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] QE II Hlth Sci Ctr, Halifax, NS, Canada
[3] Margaret & Charles Juravinski Canc Ctr, Hamilton, ON, Canada
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada
[6] Natl Canc Inst, Clin Trials Grp, Kingston, ON, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3288
引用
下载
收藏
页码：896A / 896A
页数：1
相关论文
共 50 条
  • [41] A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).
    Rossi, Jean-Francois
    Moreaux, Jerome
    Rose, Mikaelle
    Picard, Marie
    Ythier, Arnaud
    Rossier, Ciara
    Sievers, Eric
    Klein, Bernard
    BLOOD, 2006, 108 (11) : 1022A - 1022A
  • [42] A phase II study of the prateasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
    Brown, J
    Von Roenn, J
    O'Regan, R
    Bergan, R
    Badve, S
    Rademaker, A
    Feehan, S
    Petersen, J
    Patton, M
    Gradishar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 14S - 14S
  • [43] Phase II study of bortezomib in Waldenstrom's Macroglobulinemia: Results of WMCTG trial 03-248.
    Treon, S
    Hunter, ZR
    Matous, J
    Badros, A
    Joyce, RM
    Mannion, B
    Advani, R
    Cook, D
    Songer, J
    Hill, J
    Kaden, BR
    Sharon, D
    Steiss, R
    Branagan, AR
    Patterson, CJ
    BLOOD, 2005, 106 (11) : 147A - 147A
  • [44] A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gonzalo Gomez-Abuin
    Eric Winquist
    Walter M. Stadler
    Greg Pond
    Pamela Degendorfer
    John Wright
    Malcolm J. Moore
    Investigational New Drugs, 2007, 25 : 181 - 185
  • [45] A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
    Gomez-Abuin, Gonzalo
    Winquist, Eric
    Stadler, Walter M.
    Pond, Greg
    Degendorfer, Pamela
    Wright, John
    Moore, Malcolm J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (02) : 181 - 185
  • [46] A phase II Bayesian sequential clinical trial in advanced Waldenstrom macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone
    Leblond, Veronique
    Morel, Pierre
    Dilhuidy, Marie-Sarah
    Leleu, Xavier
    Soussain, Carole
    Leprete, Stephane
    Dreyfus, Brigitte
    Dartigeas, Caroline
    Mahe, Beatrice
    Anglaret, Bruno
    Pegourie, Brigitte
    Besson, Caroline
    Aurran, Therese
    Vekhoff, Anne
    Tournilhac, Olivier
    Banos, Anne
    Oya, Herve
    Lejeune, Julie
    Ouzegdouh, Maya
    Chevret, Sylvie
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2615 - 2623
  • [47] Primary Therapy of Waldenstrom's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A phase II Study of the European Myeloma Network
    Dimopoulos, Meletios A.
    Garcia-Sanz, Ramon
    Gavriatopoulou, Maria
    Morel, Pierre
    Kyrtsonis, Marie-Christine
    Katodritou, Eirini
    Michalis, Eurydiki
    Kartasis, Zafiris
    Leleu, Xavier
    Palladini, Giovanni
    Tedeschi, Alessandra
    Gika, Dimitra
    Terpos, Evangelos
    Merlini, Giampaolo
    Kastritis, Efstathios
    Sonneveld, Pieter
    BLOOD, 2010, 116 (21) : 808 - 809
  • [48] Phase I study of Bortezomib (PS-341, VELCADETM), a proteasome inhibitor, in patients with refractory or relapsed acute leukemias and myelodysplastic syndromes.
    Cortes, JE
    Estey, E
    Giles, F
    O'Brien, S
    Keating, M
    McConkey, D
    Wright, J
    Schenkein, D
    Kantarjian, H
    BLOOD, 2002, 100 (11) : 560A - 560A
  • [49] A phase I/II study of atacicept, an inhibitor of APRIL and BLyS, in multiple myeloma (MM) and waldenstrom's macroglobulinemia (WM)
    Rossi, J. F.
    Moreaux, J.
    Rose, M.
    Picard, M.
    Ythier, A.
    Hausman, D.
    Klein, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 153 - 153
  • [50] A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients
    Byun, Ja Min
    Shin, Junghoon
    Kim, Sang -A
    Park, Hyunkyung
    Lee, Jiyun
    Shin, Dong-Yeop
    Hong, Junshik
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Kim, Inho
    Yoon, Sung-Soon
    Koh, Youngil
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 675 - 680
12345